PMI Reports Strong Financial Performance for 2024 with a 7.3% Revenue Increase

Feb.08.2025
PMI Reports Strong Financial Performance for 2024 with a 7.3% Revenue Increase
PMI's Q4 2024 earnings report exceeds market expectations with a 7.3% revenue increase, driven by growing smokeless product sales.

On February 6, Philip Morris International (PMI) released its fourth quarter 2024 financial report and full year performance on its official website. The report showed that fourth quarter revenue increased by 7.3% to $9.71 billion, exceeding market expectations of $9.44 billion, compared to $9.05 billion in the same period last year. Organic revenue for the 2024 fiscal year increased by 9.8% to $37.9 billion, higher than the previous fiscal year's $35.25 billion.

PMI Reports Strong Financial Performance for 2024 with a 7.3% Revenue Increase
PMI 2024 Q4 financial report screenshot | Image source: PMI official website

 

In the fourth quarter, total sales increased by 2.9% to 193.1 billion units, with the sales of heated tobacco pods rising by 5.1% to 35.7 billion units, and sales of oral nicotine products increasing by 22.0% to 4.6 billion bags. Non-smoking product revenue accounted for 40% of total revenue, with gross profit accounting for approximately 42% and sales volume making up 20.9%. The total units (units, bags) of non-smoking business achieved quarterly shipments exceeding 40 billion for the first time, and have been launched in 95 markets, with a user base of 38.6 million, an increase of 5.3 million users compared to December 2023.

PMI Reports Strong Financial Performance for 2024 with a 7.3% Revenue Increase
PMI 2024 Performance Snapshot | Image source: PMI Official Website

 

In the 2024 fiscal year, total sales volume increased by 2.9% to 774 billion units (cigarettes, pods), with heated tobacco products growing by 11.6% and oral nicotine products growing by 24.6%.

 

PMI emphasizes that IQOS continues to be the second-largest nicotine "brand" in the existing market, driving a 0.7% increase in total sales volume in the cigarette and HTU (heated tobacco unit) industry in the fourth quarter; in Japan, the heated tobacco product ILUMA i is driving growth for IQOS, with sales volume in the domestic market increasing by about 13% in the adjusted fourth quarter and full year of 2024; in Europe, IQOS market share increased by 0.9% to 10.6% in the fourth quarter.

 

VEEV e-cigarettes ranked among the top three in 13 European markets, with the top spot in five markets including Italy, Romania, Czech Republic, Slovakia, and Finland, with an annual shipment volume of 1.7 billion units (including pods), more than doubling compared to 2023. In terms of oral nicotine products, ZYN's strong performance in the United States drove growth, with a 42% increase in shipment volume in the fourth quarter reaching nearly 165 million cans, with over double the volume of nicotine pouches sold outside the US, with significant contributions from Pakistan, South Africa, UK, and Mexico. PMI's nicotine pouches are now available in 37 markets, including recent launches in Italy, Romania, and Thailand.

 

PMI's CEO Jacek Olczak stated that,

 

In 2024, it was an exceptional year for PMI. We achieved strong annual performance, driven by the continued growth of IQOS and ZYN, as well as strong performance in combustibles.

 

Currently, the FDA has approved all ZYN nicotine pouches that we sell in the United States, further proving the compelling scientific evidence supporting smoke-free products. We hope our other pending FDA applications will be expedited. We also hope other countries will follow suit and implement effective tobacco harm reduction measures. This is especially important in places where smoke-free products are banned because they can lead to the continued presence of combustible cigarette consumption.

 

With strong momentum across all categories, we believe that our smoke-free transition and brand portfolio will continue to deliver excellent performance in 2025 and beyond, creating value for our shareholders.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
U.S. nicotine pouch startup Skoka Inc. has raised $21.5 million and committed $15 million to an FDA regulatory and scientific research program. Founder Dan Aziz previously built dietary supplement brand Premama, which was acquired by Dr. Reddy's Laboratories in 2023. Skoka is combining proprietary formulations, ingredient transparency and equity investment from professional athletes. The company submitted a bundled PMTA covering 55 products on October 1, 2026. Aziz said Skoka declined an opportunity to enter retail in 2025, prioritizing product research and regulatory submissions instead. It now targets a U.S. retail launch in 2027, subject to FDA requirements. Its products have not received marketing authorization.
Business
Nov.04
Product | Juul Labs Launches Upgraded JUUL2 Kit in UK With Four Pods at £9.99 and USB-C Charging
Product | Juul Labs Launches Upgraded JUUL2 Kit in UK With Four Pods at £9.99 and USB-C Charging
Juul Labs UK has introduced an upgraded JUUL2 Starter Kit for the UK market in October 2026, retaining a recommended retail price of £9.99 while doubling the number of included pods from two to four. The kit contains Crisp Menthol, Virginia Tobacco, Mango and Watermelon pods. The updated device replaces the previous proprietary charging dock with a USB-C port and offers longer battery life. The kit also features reduced packaging and retains a two-year limited warranty. Distribution is scheduled through major UK retailers, wholesalers, convenience stores and the JUUL UK website.
product
Oct.15
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
South Korea's Tobacco Plan Excludes 6-Methyl Nicotine as Customs Tightens Import Controls and Analog Liquid Imports Fall 83%
South Korea's Tobacco Plan Excludes 6-Methyl Nicotine as Customs Tightens Import Controls and Analog Liquid Imports Fall 83%
South Korea's government unveiled its first Tobacco Harm Management Basic Plan for 2027–2031 on October 29, 2026, proposing broader testing of vaping and heated tobacco products while excluding nicotine analogs such as 6-methyl nicotine. Synthetic nicotine came under tobacco regulation on April 24, and a June investigation found 6-methyl nicotine in 12 liquid inhalation products marketed as nicotine-free. Customs data released in September showed that imports of nicotine analog solutions fell 83.3%, from 12 metric tons in January–April to 2 metric tons in May–August. By September 20, imports had reached approximately 15 metric tons for the year, with 99.99% originating from China. Customs authorities have tightened pre-clearance testing and supply-chain documentation requirements, while the MFDS expects to complete its assessment of nicotine analog hazards by the end of 2026.
Regulations
Nov.04
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23